Miami, FL – According to filings with the U.S. Securities and Exchange Commission, Aegle Therapeutics is raising $6,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Shelley Hartman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aegle Therapeutics

Aegle Therapeutics is a first in class, phase 1/2a stage biotechnology company isolating extracellular vesicles including exosomes (EVs) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (DEB), a rare pediatric connective tissue disorder. Aegle’s EV therapy, using its proprietary platform isolation technology, is cell-free and has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can enhance healing, reduce scarring, minimize contraction and improve overall cosmesis.

To learn more about Aegle Therapeutics, visit http://www.aegletherapeutics.com/

Contact:
Shelley Hartman, Chief Executive Officer
305-243-4589
https://www.linkedin.com/in/shelley-hartman-75039135/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved